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8 Abstract Approximately 20 % of human breast cancers
9 (BC) overexpress HER2 protein, and HER2-positivity is
10 associated with a worse prognosis. Although HER2-tar-
11 geted therapies have signiﬁcantly improved outcomes for
12 HER2-positive BC patients, resistance to trastuzumab-
13 based therapy remains a clinical problem. In order to better
14 understand resistance to HER2-targeted therapies in HER2-
15 positive BC, it is necessary to examine HER family sig-
16 nalling as a whole. An extensive literature search was
17 carried out to critically assess the current knowledge of
18 HER family signalling in HER2-positive BC and response
19 to HER2-targeted therapy. Known mechanisms of trast-
20 uzumab resistance include reduced receptor-antibody
21 binding (MUC4, p95HER2), increased signalling through
22 alternative HER family receptor tyrosine kinases
23 (RTK), altered intracellular signalling involving loss of
24 PTEN, reduced p27kip1, or increased PI3 K/AKT activity
25 and altered signalling via non-HER family RTKs such as
26 IGF1R. Emerging strategies to circumvent resistance to
27HER2-targeted therapies in HER2-positive BC include co-
28targeting HER2/PI3 K, pan-HER family inhibition, and
29novel therapies such as T-DM1. There is evidence that
30immunity plays a key role in the efﬁcacy of HER-targeted
31therapy, and efforts are being made to exploit the immune
32system in order to improve the efﬁcacy of current anti-HER
33therapies. With our rapidly expanding understanding of
34HER2 signalling mechanisms along with the repertoire of
35HER family and other targeted therapies, it is likely that the
36near future holds further dramatic improvements to the
37prognosis of women with HER2-positive BC.
38
39Keywords Trastuzumab · HER2 · Breast cancer ·
40PI3 K
41Introduction
42BC is the second most common cancer in the world, and the
43ﬁfth highest cause of cancermortalityworldwide [1]. 20%of
44human BC’s overexpress HER2, and HER2-positivity is
45associated with a signiﬁcantly worse prognosis. HER2 ﬁrst
46became targetable in patients with trastuzumab (Herceptin,
47™ Genentech/Roche), a monoclonal antibody that has sig-
48niﬁcantly improved outcomes for patients with HER2-
49positive BC, but the efﬁcacy of trastuzumab is limited in
50some patients by acquired and de novo resistance [2].
51HER family signalling
52There are 20 known RTK families: since members of over
53half of these have been found to be mutated or overex-
54pressed in diseases marked by abnormal proliferation,
55RTK’s have been considered potential targets for cancer
56therapy. HER2, a type 1 transmembrane protein RTK, and
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57 an oncogenic driver of the growth of HER2-positive BC, is
58 associated with a shorter time to relapse and decreased
59 overall survival (OS). A meta-analysis in 2003 found that
60 of 81 studies spanning sixteen years of research and
61 incorporating 27,161 patients [3], HER2 overexpression
62 predicted a worse BC outcome. In contrast to the other
63 known HER family members, those being epidermal
64 growth factor receptor (EGFR/HER1), HER3 and HER4,
65 no ligand has yet been identiﬁed for HER2 (Fig. 1). When
66 overexpressed, HER2 exists in a constitutively open con-
67 formation, leaving it intrinsically capable of interacting
68 with available RTK binding partners even in the absence of
69 ligand [4]. HER family ligands induce quantitative differ-
70 ences in receptor phosphorylation but quantitatively similar
71 physiological responses, suggesting that the identity of
72 activated receptors, rather than the number of activated
73 receptors, determines the cellular response [5]. Coordi-
74 nated overexpression of EGFR and HER2 frequently
75 occurs in HER2-positive BC. Expression proﬁling has
76 identiﬁed at least two subgroups within HER2-positive
77 primary breast tumours. Many of the differently expressed
78 genes track with oestrogen receptor (ER) status, suggesting
79 that HER2+/ER+ and HER2+/ER− represent two distinct
80 entities [6].
81 HER2 dimerization is mediated by the formation of
82 disulphide bonds between cysteine residues in the juxta-
83 membrane region, and disrupting these disulphide bonds
84 disrupts the ability of HER2 to transform cells [7].
85 Phosphorylated tyrosine residues on the receptor molecule
86serve as recognition and docking sites for SH2-containing
87proteins. These serve as linker molecules, recruiting
88components of downstream signalling pathways, such as
89the phosphoinositide-3-kinase (PI3 K) pathway, through
90which the activated RTK exerts its biological effect(s)
91(Fig. 1). HER family signalling is governed by a strict
92hierarchy, with HER2 the preferred dimerization partner
93of all other HER family members [8]. Cells transformed
94by HER2 display increased tyrosine phosphorylation of
95both HER2 and other proteins [9], and a recent study
96identiﬁed a subset of patients which were classed as
97HER2-negative by FISH analysis yet displayed HER2
98activation that was coincident with EGFR and HER3
99activation (n = 415) [10]. HER2/HER3 heterodimers have
100been proposed to be the main oncogenic unit in HER2-
101positive BC, with HER3 coupling activated HER2 to the
102downstream PI3 K and other pathways [11]. There is a
103correlation between simultaneous high HER2 and high
104HER3 levels and reduced sensitivity to trastuzumab [12].
105Further synergistic targeting of HER2 and HER3 was
106demonstrated to achieve higher therapeutic efﬁcacy [13],
107and the HER3 ligand neuregulin confers resistance to
108chemotherapy and has recently been implicated as a
109potential mechanism of resistance to T-DM1 [14]. In
110contrast, some studies suggest a tumour suppressor role
111for HER4 in HER2-positive BC, although this is likely to
112be isoform speciﬁc and context speciﬁc [15]. A recent
113study suggested that the localisation of HER4 may play a
114role in its activity, with nuclear, but not cytoplasmic
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115 HER4 associated with poorer survival and trastuzumab
116 resistance [16].
117 Current HER2-targeted therapies
118 First generation HER2-targeted agents
119 The ﬁrst indication that HER2-targeted therapy could attain
120 high speciﬁcity and avoid off-target toxicity came when
121 murine antibodies against HER2 were shown to selectively
122 inhibit growth of neu-transformed cells, but not ras-trans-
123 formed cells [17]. Subsequently, a humanised mAb against
124 HER2 inhibited proliferation of HER2-ampliﬁed cells
125 in vitro, and enhanced the antitumour effect of paclitaxel
126 and doxorubicin in xenograft models of HER2-positive BC
127 [18]. That trastuzumab signiﬁcantly improves outcomes for
128 HER2-positive BC patients is now well established
129 (Table 1), although its mechanism of action remains
130 incompletely deﬁned.
131 Potential mechanisms include inhibition of HER2
132 dimerization [4], inhibition of cleavage of the ectodomain
133 of activated HER2 [19], induction of p27
KIP1 [20], inhibi-
134 tion of PI3 K signalling, downregulation of HER2 leading
135 to enhanced apoptosis mediated by tumour necrosis factor
136 alpha-related apoptosis inducing ligand [21], and antibody-
137 dependent cell-mediated cytotoxicity [22]. Trastuzumab-
138 mediated internalisation and degradation of HER2 may
139 inhibit receptor signalling, although some studies report
140 that receptor levels are unaffected by trastuzumab treat-
141 ment [23]. Despite its beneﬁts, trastuzumab is limited in
142 some patients by de novo and acquired resistance, and
143 because it cannot cross the blood-brain barrier. Approxi-
144 mately 35 % of metastatic HER2-positive BC patients
145 treated with trastuzumab go on to develop brain metastases
146 [24].
147 Lapatinib (Tykerb,™ GlaxoSmithKline) is an orally
148 bioavailable small molecule tyrosine kinase inhibitor (TKI)
149 targeted to EGFR and HER2. Pre-clinical [25] and clinical
150 [26] evidence shows that lapatinib is effective against
151 trastuzumab-resistant HER2-positive BC, and it is cur-
152 rently used as subsequent therapy for patients with disease
153 that has progressed on trastuzumab. Lapatinib inhibits
154 HER2 phosphorylation more strongly than trastuzumab,
155 and unlike trastuzumab, it inhibits extracellular signal-
156 related kinase (Erk) 1 and 2 as well as PI3 K in vivo [27,
157 28]. Lapatinib inhibited tumour growth in p95HER2-
158 overexpressing pre-clinical mouse models and has shown
159 clinical beneﬁt in patients refractory to trastuzumab whose
160 tumours overexpressed p95HER2 (n = 537) [26]. It
161 inhibits the development of brain metastases in vivo [24]
162 and has modest activity against HER2-positive brain
163 metastases clinically (n = 242) [29]. Trastuzumab and la-
164 patinib have complementary mechanisms of action, and the
165combination of both [30, 31] confers an OS beneﬁt in
166patients with heavily pretreated, trastuzumab-resistant
167HER2-positive metastatic BC compared to lapatinib
168monotherapy [32]. However, the success of lapatinib has
169been hit by a number of recent disappointing clinical trial
170results including the adjuvant study ALTTO [33], a number
171of neoadjuvant studies, and the NCIC CTG ﬁrst-line met-
172astatic study [34] (Table 1). These studies, along with the
173success of pertuzumab and T-DM1, mean that lapatinib’s
174place in the clinic remains in patients with HER2-positive
175metastatic BC, who have received at least 1–2 prior lines of
176therapy for metastatic disease.
177Second generation HER2-targeted agents
178Pertuzumab (Omnitarg ™, Genentech) is a humanised
179monoclonal antibody which binds to HER2’s extracellular
180domain II, which is involved in dimerization [4]. This is in
181contrast to trastuzumab, which binds to domain IV. Pert-
182uzumab thus blocks HER2/HER3 interaction, diminishes
183ligand-activated HER2 signalling in BC cell lines, and
184inhibits the growth of high- and low-HER2-expressing
185HER2-positive breast xenografts in vivo [35, 36]. The
186combination of trastuzumab and pertuzumab in vivo results
187in an additive increase in ADCC and marked regression of
188metastatic HER2-positive BC in treated animals [37]. In
189clinical trials, pertuzumab signiﬁcantly improved patient
190outcomes when added to trastuzumab and docetaxel in
191ﬁrst-line metastatic HER2-positive BC and in the neoad-
192juvant setting (Table 1). Other trials with pertuzumab are
193ongoing (Table 3).
194Trastuzumab-emtansine (T-DM1, Genentech) is an
195antibody-drug conjugate (ADC) which links trastuzumab to
196a highly cytotoxic maytansinoid agent, emtansine, which
197binds tubulin and arrests mitosis at metaphase [38]. Fol-
198lowing the binding of T-DM1 to HER2, receptor-mediated
199internalisation transports it to the cytoplasm, where lyso-
200somal degradation releases and activates the cytotoxic
201agent [39]. In addition to the anti-mitotic properties of
202emtansine, T-DM1 retains the mechanisms of action of
203trastuzumab including initiation of ADCC, inhibition of
204HER2 shedding and downregulation of PI3 K/AKT path-
205way activity, and is effective in models of lapatinib-
206resistance in vitro [40]. TDM-1 is now in clinical use in the
207second-line setting in metastatic HER2-positive BC based
208on the results of the EMILIA study [41] (Table 1).
209The role of immunology in HER2-targeted therapy
210There is compelling pre-clinical evidence of the impor-
211tance of the immune response in the efﬁcacy of
212trastuzumab in HER2-positive disease, and from a clinical
213perspective, data point to HER2-positive and triple
Breast Cancer Res Treat
123
Journal : Large 10549 Dispatch :22-12-2014 Pages :11
Article No. :3250
LE TYPESET
MS Code :BREA-D-14-00867 CP DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
T
a
b
le
1
S
ig
n
iﬁ
ca
n
t
cl
in
ic
al
tr
ia
ls
o
f
H
E
R
2
-t
ar
g
et
ed
th
er
ap
ie
s
co
m
p
le
te
d
to
d
at
e
in
H
E
R
2
-p
o
si
ti
v
e
B
C
C
li
n
ic
al
tr
ia
l
D
et
ai
ls
S
am
p
le
si
ze
F
in
d
in
g
s
T
ra
st
u
zu
m
ab
-b
as
ed
tr
ia
ls
H
0
6
4
8
g
[ 7
3
]
A
d
ju
v
an
t
ch
em
o
th
er
ap
y
±
tr
as
tu
zu
m
ab
4
6
9
R
el
at
iv
e
ri
sk
o
f
d
ea
th
re
d
u
ce
d
b
y
2
0
%
an
d
lo
n
g
er
ti
m
e
to
d
is
ea
se
p
ro
g
re
ss
io
n
w
it
h
tr
as
tu
zu
m
ab
(7
.4
v
s
4
.6
m
o
n
th
s,
P
\
0
0
1
)
H
E
R
A
[7
4
]
A
d
ju
v
an
t
ch
em
o
th
er
ap
y
±
tr
as
tu
zu
m
ab
4
,4
8
2
2
4
%
re
d
u
ct
io
n
o
f
re
cu
rr
en
ce
w
it
h
tr
as
tu
zu
m
ab
(P
\
0
.0
0
0
1
)
N
C
C
T
G
N
9
8
3
1
/N
S
A
B
P
B
-3
1
[7
5
]
A
d
ju
v
an
t
ch
em
o
th
er
ap
y
±
tr
as
tu
zu
m
ab
4
,4
0
5
4
8
%
re
la
ti
v
e
re
d
u
ct
io
n
in
d
is
ea
se
-f
re
e
su
rv
iv
al
(D
F
S
)
(P
\
0
.0
0
1
)
an
d
3
9
%
re
la
ti
v
e
re
d
u
ct
io
n
in
o
v
er
al
l
su
rv
iv
al
(O
S
)
ev
en
ts
(P
\
0
.0
0
1
)
w
it
h
tr
as
tu
zu
m
ab
B
C
IR
G
0
0
6
[7
6
]
A
d
ju
v
an
t
ch
em
o
th
er
ap
y
±
1
y
ea
r
o
f
tr
as
tu
zu
m
ab
3
,2
2
2
O
n
e
y
ea
r
o
f
tr
as
tu
zu
m
ab
si
g
n
iﬁ
ca
n
tl
y
im
p
ro
v
ed
D
F
S
(8
v
s
7
5
%
,
P
\
0
.0
0
1
)
an
d
O
S
(9
2
v
s
8
7
%
,
P
\
0
.0
0
1
)
N
O
A
H
[7
7
]
N
eo
ad
ju
v
an
t
ch
em
o
th
er
ap
y
±
n
eo
ad
ju
v
an
t
tr
as
tu
zu
m
ab
2
3
5
A
lm
o
st
d
o
u
b
le
th
e
ra
te
o
f
p
C
R
to
th
er
ap
y
,
si
g
n
iﬁ
ca
n
tl
y
im
p
ro
v
ed
ev
en
t-
fr
ee
su
rv
iv
al
w
it
h
tr
as
tu
zu
m
ab
(7
1
v
s
5
6
%
,
P
=
0
.0
1
3
)
L
ap
at
in
ib
-b
as
ed
tr
ia
ls
N
C
T
0
0
0
7
8
5
7
2
[7
8
]
C
ap
ec
it
ab
in
e
±
la
p
at
in
ib
in
H
E
R
2
+
m
et
as
ta
ti
c
B
C
p
at
ie
n
ts
w
it
h
d
is
ea
se
th
at
h
ad
p
ro
g
re
ss
ed
o
n
tr
as
tu
zu
m
ab
3
9
9
5
1
%
re
d
u
ce
d
ri
sk
o
f
p
ro
g
re
ss
io
n
an
d
im
p
ro
v
ed
D
F
S
(8
.4
m
o
n
th
s
v
s
4
.4
m
o
n
th
s,
P
\
0
.0
0
1
)
w
it
h
o
u
t
a
si
g
n
iﬁ
ca
n
t
O
S
im
p
ro
v
em
en
t
w
it
h
la
p
at
in
ib
N
S
A
B
P
B
-4
1
[7
9
]
N
eo
ad
ju
v
an
t
la
p
at
in
ib
p
lu
s
ch
em
o
th
er
ap
y
v
s
n
eo
ad
ju
v
an
t
tr
as
tu
zu
m
ab
p
lu
s
ch
em
o
th
er
ap
y
5
1
9
S
im
il
ar
p
C
R
ra
te
s
b
et
w
ee
n
tr
as
tu
zu
m
ab
(5
2
.5
%
)
an
d
la
p
at
in
ib
(5
3
.2
%
),
an
d
a
n
o
n
-s
ig
n
iﬁ
ca
n
t
in
cr
ea
se
in
p
C
R
(P
=
0
.0
9
5
)
w
it
h
b
o
th
tr
as
tu
zu
m
ab
an
d
la
p
at
in
ib
co
m
p
ar
ed
to
th
e
u
se
o
f
ei
th
er
al
o
n
e
C
H
E
R
-L
O
B
[ 5
0
]
N
eo
ad
ju
v
an
t
ch
em
o
th
er
ap
y
p
lu
s
tr
as
tu
zu
m
ab
,
la
p
at
in
ib
,
o
r
b
o
th
1
2
1
S
ig
n
iﬁ
ca
n
t
re
la
ti
v
e
in
cr
ea
se
in
p
C
R
(8
0
%
,
P
=
0
.0
1
9
)
w
it
h
b
o
th
tr
as
tu
zu
m
ab
an
d
la
p
at
in
ib
co
m
p
ar
ed
to
ei
th
er
al
o
n
e
A
L
T
T
O
[3
3
]
O
n
e
y
ea
r
o
f
tr
as
tu
zu
m
ab
al
o
n
e,
o
n
e
y
ea
r
o
f
la
p
at
in
ib
al
o
n
e,
th
ei
r
se
q
u
en
ce
o
r
co
m
b
in
at
io
n
in
th
e
ad
ju
v
an
t
tr
ea
tm
en
t
o
f
H
E
R
2
-p
o
si
ti
v
e
ea
rl
y
B
C
8
,3
8
1
N
o
n
si
g
n
iﬁ
ca
n
t
re
d
u
ct
io
n
in
D
F
S
w
it
h
b
o
th
la
p
at
in
ib
an
d
tr
as
tu
zu
m
ab
co
m
p
ar
ed
to
tr
as
tu
zu
m
ab
al
o
n
e
(8
8
%
v
s
8
6
%
,
P
=
0
.0
4
8
)
N
eo
A
L
T
T
O
[8
0
]
N
eo
ad
ju
v
an
t
tr
as
tu
zu
m
ab
,
la
p
at
in
ib
o
r
a
co
m
b
in
at
io
n
o
f
b
o
th
4
5
5
S
ig
n
iﬁ
ca
n
tl
y
im
p
ro
v
ed
p
C
R
(P
\
0
.0
1
)
to
th
e
co
m
b
in
at
io
n
o
f
tr
as
tu
zu
m
ab
an
d
la
p
at
in
ib
(5
1
.3
%
)
co
m
p
ar
ed
to
th
at
o
f
tr
as
tu
zu
m
ab
al
o
n
e
(2
9
.5
%
)
N
C
IC
C
T
G
[3
4
]
L
ap
at
in
ib
+
ch
em
o
th
er
ap
y
v
s
tr
as
tu
zu
m
ab
+
ch
em
o
th
er
ap
y
as
ﬁ
rs
t-
li
n
e
tr
ea
tm
en
t
fo
r
w
o
m
en
w
it
h
m
et
as
ta
ti
c
H
E
R
2
-
p
o
si
ti
v
e
B
C
6
3
6
S
in
g
n
iﬁ
ca
n
tl
y
re
d
u
ce
d
P
F
S
(P
=
0
.0
1
)
w
it
h
la
p
at
in
ib
+
ch
em
o
th
er
ap
y
co
m
p
ar
ed
to
tr
as
tu
zu
m
ab
+
ch
em
o
th
er
ap
y
(8
.8
m
o
n
th
s
co
m
p
ar
ed
to
1
1
.4
m
o
n
th
s)
P
er
tu
zu
m
ab
-b
as
ed
tr
ia
ls
C
L
E
O
P
A
T
R
A
[ 8
1
]
T
ra
st
u
zu
m
ab
an
d
d
o
ce
ta
x
el
±
p
er
tu
zu
m
ab
in
ﬁ
rs
t-
li
n
e
tr
ea
tm
en
t
o
f
H
E
R
2
-p
o
si
ti
v
e
m
et
as
ta
ti
c
B
C
p
at
ie
n
ts
8
0
8
P
ro
lo
n
g
ed
D
F
S
,
si
g
n
iﬁ
ca
n
tl
y
im
p
ro
v
ed
O
S
(1
7
.2
v
s
2
3
.6
%
,
P
=
0
.0
0
5
)
an
d
3
4
%
re
d
u
ce
d
ri
sk
o
f
d
ea
th
w
it
h
p
er
tu
zu
m
ab
N
eo
S
p
h
er
e
[7
7
]
N
eo
ad
ju
v
an
t
tr
as
tu
zu
m
ab
an
d
d
o
ce
ta
x
el
±
p
er
tu
zu
m
ab
in
w
o
m
en
w
it
h
lo
ca
ll
y
ad
v
an
ce
d
,
in
ﬂ
am
m
at
o
ry
o
r
ea
rl
y
H
E
R
2
-p
o
si
ti
v
e
B
C
4
1
7
S
ig
n
iﬁ
ca
n
tl
y
h
ig
h
er
p
C
R
w
it
h
p
er
tu
zu
m
ab
(4
5
.8
v
s
2
9
.0
%
,
P
=
0
.0
1
4
).
F
u
rt
h
er
,
1
7
%
o
f
p
at
ie
n
ts
g
iv
en
tr
as
tu
zu
m
ab
an
d
p
er
tu
zu
m
ab
w
it
h
o
u
t
ch
em
o
th
er
ap
y
ac
h
ie
v
ed
p
C
R
Breast Cancer Res Treat
123
Journal : Large 10549 Dispatch :22-12-2014 Pages :11
Article No. :3250
LE TYPESET
MS Code :BREA-D-14-00867 CP DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
219negative as the breast cancer subtypes with the most con-
220sistent association between immune inﬁltration and good
221prognosis [42]. The interaction of monoclonal antibody
222therapies with Fcγ receptors expressed on effector immune
223cells is the basis of ADCC, [43] and the association
224between tumour-inﬁltrating lymphocytes and beneﬁt from
225trastuzumab and chemotherapy has been observed in The
226FinHER and GeparQuattro trials [44, 45]. Prospective
227analysis of BIG 02-98 showed increasing stromal lym-
228phocyte inﬁltration (10 % increments) was related to
229beneﬁt from adjuvant anthracycline-only chemotherapy in
230HER2-positive disease [46] suggesting lymphocyte pre-
231dominant BC status may have repercussions for anticipated
232response to classical chemotherapies as well as newer
233targeted therapies. Cytotoxic drugs may also alter the
234immune response directly and these effects may play a
235major role in the efﬁcacy of chemotherapy [47].
236Efforts have been made to improve the effector function
237of mAb therapies as a strategy to enhance their efﬁcacy.
238Afucosylated trastuzumab has shown enhanced ADCC
239function and efﬁcacy in vitro and in vivo pre-clinical tests
240[48]. Margetuximab (MGAH22) is an Fc-optimised anti-
241HER2 antibody proteolytic cleavage has been shown to
242reduce the ADCC function of trastuzumab in a pre-clinical
243study and could be the basis for reduced trastuzumab
244efﬁcacy in matrix metalloprotease-rich tumours [49]. Pro-
245tease resistant antibodies maintaining effector function are
246being developed [50].
247An IgE-homologue of trastuzumab (containing an epsi-
248lon in the place of the gamma-1 heavy chain constant
249region) has been shown to initiate monocyte-mediated
250ADCC against HER2-positive breast cancer cells [51].
251Trastuzumab IgE also induced mast cell degranulation
252which is capable of triggering a potent antitumour immune
253response in vivo with pre-clinical studies point to improved
254efﬁcacy compared to IgG1 equivalents providing support
255for clinical evaluation [52].
256CD137, a member of the tumour necrosis factor (TNF)
257receptor family, is upregulated on human natural killer
258cells following exposure to trastuzumab-treated HER2-
259positive tumour cells [53]. In vitro and in vivo studies have
260shown that the ADCC response to monoclonal antibody
261therapies including trastuzumab is augmented through
262stimulation of the CD137 receptor on NK cells with an
263agonistic antibody therapy [53–55]. Anti-CD137 agonistic
264antibodies are currently in Phase I and II clinical trials [42].
265Adaptive immune response
266Murine models have been used to exhibit the importance of
267Fcγ receptors and T cells in an effective response to
268trastuzumab in vivo, providing the basis of a link between
269NK cell induced trastuzumab-mediated ADCC and theT
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270 adaptive immune response [56]. A more recent study has
271 shown that tumour cells from patients expressing a breast
272 cancer stem cell-related marker (ALDH1) evade direct NK
273cell cytotoxicity through downregulation of the NKG2D
274ligands, MICA and MICB resulting in increased metastases
275[57]. Increases in NK2GD and DNAM1 ligands in response
Table 2 Mechanisms of Resistance HER2-targeted therapies in HER2-positive BC
Biomarker Mechanism Known to mediate
resistance to
Shown
in vitro
Shown
in vivo
Clinical
studies
Possible
targeting
strategies
PIK3CA
mutation
HER2-independent activation of
the PI3 K pathway downstream
from HER2
Trastuzumab/
Lapatinib
Yes [2] Yes [51] Yes [2, 46, 54, 56] Cotarget PI3 K/
HER2
PTEN loss HER2-independent activation of
the PI3 K pathway downstream
of HER2
Trastuzumab/
Lapatinib
Yes [51, 84] Yes [51] Yes [46] Cotarget PI3 K/
HER2
p95HER2 Lacks extracellular antibody
binding domain but retains full
kinase activity
Trastuzumab Yes [85] Yes [85, 86] Yes [12] [49, 87] Lapatinib/novel
TKI’s
MUC4 Masks trastuzumab binding site Trastuzumab Yes [45] Yes [45] No Lapatinib/novel
TKI’s
MET receptor Upregulates AKT and abrogates
p27 induction in response to
trastuzumab
Trastuzumab Yes [88] No Yes [89] MET inhibition
IGF1R Heterodimerizes with HER2 to
activate downstream signalling
Trastuzumab Yes [47] No Yes [47] Co-target
IGF1R/HER2
Inhibition/loss
of P27Kip1
Impairs anti-HER2 antibody
induced cell cycle arrest,
thereby increasing proliferation
Trastuzumab Yes [20] No Yes [90] None currently
available
IGF1R insulin-like growth factor-1 receptor, MUC4 mucin-4, PTEN phosphatase and tensin deleted in chromosome 10
Table 3 Important ongoing clinical trials with novel HER2-targeted therapies in HER2-positive BC
Trial Setting Sample size Aims/arms/investigation Results expected
Pertuzumab-based trials
Pherexa HER2-positive BC patients who
progressed following
trastuzumab
450 Trastuzumab and
capecitabine ± pertuzumab
June 2017
Aphinity Early stage HER2-positive BC 3,806 (estimated
enrolment)
Adjuvant chemotherapy and
trastuzumab ± pertuzumab
December 2023
T-DM1-based trials
Marianne Metastatic HER2-positive BC 1,095 Combination pertuzumab and
T-DM1
April 2016
Katherine HER2-positive BC with residual
tumour in breast/lymph nodes
following preoperative therapy
1,484 (estimated
enrolment)
Adjuvant trastuzumab vs adjuvant
T-DM1
March 2023
Neratinib-based trials
ExteNET Early stage HER2-positive BC 2,842 Neratinib after adjuvant
trastuzumab on overall survival
Completed, not yet reported
NALA Metastatic HER2-positive BC 600 (estimated
enrolment)
Neratinib plus capecitabine vs
lapatinib plus capecitabine
May 2018
Afatinib-based trials
Lux-Breast 1 HER2-positive metastatic BC
patients who have progressed on
trastuzumab
508 (estimated
enrolment)
Afatinib plus vinolrebine vs.
trastuzumab plus vinolrebine
June 2014
Lux-Breast 3 HER2-positive BC patients with
brain metastasis
120 Vinorelbine ±/− Afatinib September 2014
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276 to taxane treatment have been shown to increase trast-
277 uzumab-mediated ADCC in HER2-positive cell line
278 models [58]. This may provide further indications for the
279 importance of trastuzumab alone and in combination with
280 chemotherapy in the treatment of HER2-expressing breast
281 cancer.
282 Monoclonal antibody therapies like trastuzumab, pert-
283 uzumab, TDM1 and anti-PD-1/PD-L1 could be considered
284 passive immunotherapies. The exclusive localisation of
285 HER2 overexpression in tumours also makes HER2 an
286 attractive target for active immunotherapies. Some patients
287 are capable of producing a speciﬁc anti-HER2 response
288 involving cellular and humoral immunity [59, 60]. Peptide-
289 based vaccines aim to elicit an immune response using
290 epitopes from tumour-associated antigens. E75, consisting
291 of HER2 amino acids 369–377, is the most extensively
292 studied peptide-based vaccine in the clinic. Phase I studies
293 in the metastatic setting showed that the combination of
294 E75 with an adjuvant was safe and generated cytotoxic T
295 lymphocyte responses [61]. Combined analysis of two tri-
296 als combining escalating E75 doses and GM-CSF in the
297 adjuvant setting found that DFS was 94 versus 79.4 % in
298 the vaccine group and control group, respectively, at
299 24 months, [62] and a trend towards reduced recurrence
300 was observed in optimally dosed patients. [63] Protein-
301 based vaccines utilise entire or truncated forms of HER2 in
302 order to take advantage of HLA-I and HLA-II class epi-
303 topes within HER2 and therefore potentially activate a
304 CD4+ T cell response. One clinical study has reported
305 limited tumour regression (2/42 patients) [64, 65]. DNA
306 vaccines and whole cell (autologous or allogeneic) vac-
307 cines are designed to interact with antigen presenting cells
308 (APCs) with subsequent activation of T cells. These have
309 been shown to produce a pronounced immune response
310 which included antibody production with no dose limiting
311 toxicity in the metastatic setting (n = 28) [66]. Dendritic
312 cells (DC) are potent APCs, expressing HLA-CLASS I and
313 II, T cell co-stimulatory factors and producing T cell
314 stimulating cytokines [67]. Dendritic cell vaccines are in
315 the preliminary phase of development. Clinical studies
316 examining combinations of active and passive immuno-
317 therapies are ongoing with the hope that these
318 combinations will produce increased immunological
319 responses [68].
320 Mechanisms of resistance to HER2-targeted therapies
321 Many potential mechanisms of trastuzumab resistance in
322 HER2 positive BC have been proposed (Table 2); these
323 include reduced receptor-antibody binding due to increased
324 HER2 masking [69]; increased signalling through alterna-
325 tive HER family RTKs[12]; altered intracellular signalling
326 involving loss of PTEN, reduced p27kip1, or increased
327PI3 K/AKT activity (e.g. by PIK3CA mutations) [70]; and
328altered signalling via non-HER family RTKs [71, 72].
329P95HER2, which lacks an extracellular domain but retains
330kinase activity, has been proposed as a mechanism of
331resistance [73]. However, it was not shown to have a sig-
332niﬁcant association with pCR clinically, [74] and
333difﬁculties in developing a robust clinical assay for
334p95HER2 have prevented its introduction as a clinically
335relevant biomarker.
336Clinical studies provide strong evidence that the PI3 K
337pathway is involved in trastuzumab resistance, reﬂecting
338in vitro observations that the PI3 K pathway is involved in
339both trastuzumab and lapatinib resistance [75]. Pre-clinical
340studies have demonstrated that AKT can be activated
341independently of HER2 [2]. Such HER2-independent
342PI3 K pathway activation may result from aberrant RTK
343signalling upstream of PI3 K, PTEN loss or PIK3CA
344mutations and lead to less dependency on HER family
345signalling for tumourigenesis [75], indicating that HER2
346inhibition without co-inhibition of the PI3 K pathway may
347not be sufﬁcient to inhibit tumour growth in some HER2-
348positive BC’s. Patients with PI3 K pathway activation in
349their HER2-positive BC have shorter OS and a worse
350response to trastuzumab [70, 76]. Although some reports
351are conﬂicting in this regard [77], [78], PIK3CA mutations
352have been shown to predict resistance to HER2-targeted
353therapy-based regimens in primary HER2-positive BC [2,
35479], with one study suggesting that this effect is restricted
355to cancers that are HER2+/ER+ [80].
356argeting the PI3 K pathway
357Pre-clinical data consistently suggest that targeting PI3 K
358pathway signalling nodes downstream from HER2 (e.g.
359mammalian target of rapamycin (mTOR) or PI3 K itself) in
360addition to targeting HER2 will overcome resistance of
361HER2-ampliﬁed BC to HER2-targeted therapies in some
362cases [81].
363mTOR, a serine/threonine kinase, is a downstream
364component of the PI3 K pathway. The mTOR inhibitor
365everolimus (Aﬁnitor,™ Novartis) improves the antitumour
366efﬁcacy of trastuzumab [82]. However, the added efﬁcacy
367of everolimus in combination with trastuzumab and vino-
368relbine in the metastatic setting was disappointing in the
369phase 3 clinical trial BOLERO-3 [82]. mTOR may thus not
370be not an optimal target for inhibiting the PI3 K pathway as
371mTOR is only one downstream target of PI3 K. Further-
372more, targeting mTOR leads to feedback loop-induced
373AKT activation, shown to signiﬁcantly decrease the anti-
374tumour efﬁcacy of mTOR inhibition [83].
375Therefore newer inhibitors of PI3 K and AKT are being
376investigated in combination with HER2-targeted therapies
377in HER2-positive BC. Examples include copanlisib, a pan-
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378 class 1 PI3 K inhibitor, GDC-0941, and dual PI3 K/mTOR
379 inhibitors GDC0980 and NVP-BEZ235 [84]. Such com-
380 pounds show clear in vitro and in vivo efﬁcacy [85] and are
381 in early clinical trials in HER2-positive breast and other
382 cancers, [86] both alone and in combination with trast-
383 uzumab[87]. The combination of the PI3 K inhibitor
384 buparlisib (BKM120) and trastuzumab was recently shown
385 to be well tolerated with preliminary signs of clinical
386 activity in HER2-positive BC patients with trastuzumab-
387 resistant disease [88]. In this trial, pharmacodynamic
388 studies showed inhibition of both the PI3 K and MAPK
389 pathways.
390 Novel HER2-targeted therapies
391 Some early phase clinical trials (Table 1) suggest encour-
392 aging efﬁcacy for the novel HER2-directed TKI’s neratinib
393 and afatinib in HER2-positive BC. Neratinib is an irre-
394 versible TKI against EGFR and HER2. It potently inhibits
395 HER2 and EGFR kinase activity, MAPK and AKT phos-
396 phorylation, and enhances p27 induction in vitro, and
397 inhibits the growth of HER2-positive tumours in vivo [89].
398 Unlike trastuzumab, it decreases phosphorylation of EGFR,
399 HER2, HER4 and ERK, and the addition of neratinib to
400 trastuzumab overcomes trastuzumab resistance in vitro
401 [90]. The combination of neratinib and vinorelbine has
402 shown signiﬁcant antitumour effects with no synergistric
403 toxicity [91].
404 Somatic, including activating, HER2 mutations have
405 recently been found to be present at a low frequency in
406 HER2-negative BC [92], suggesting that HER2-targeted
407 therapy may beneﬁt some patients who are HER2-negative
408 but bear HER2 somatic mutations. Several of those muta-
409 tions were associated with resistance to lapatinib; one
410 mutation increased the phosphorylation of EGFR and
411 HER3, suggesting that HER2 signalling could be activated
412 by HER2 somatic mutations as well as by HER2 gene
413 overexpression. Neratinib potently inhibited the growth of
414 cells bearing these HER2 mutations, including those
415 associated with lapatinib resistance.
416 Afatinib is a TKI which irreversibly binds EGFR and
417 HER2. Afatinib inhibits ligand-dependent phosphorylation of
418 HER3 [93], and demonstrates antitumour activity in patients
419 with HER2-positive BCwho have progressed on trastuzumab
420 [94]. It may also have potential to treat some patients with
421 triple-negative BC, due to its anti-EGFR activity [95]. Afati-
422 nib monotherapy may have a higher overall response rate
423 compared to both trastuzumab and lapatinib monotherapy in
424 treatment naı¨ve patients with HER2-positive, locally
425 advanced BC [96]. Table 3 lists some ongoing clinical trials
426 with neratinib and afatinib in HER2-positive BC.
427Conclusion
428The HER family is a group of related RTKs that signal
429cooperatively to mediate oncogenic effects. One member,
430HER2, is overexpressed by gene ampliﬁcation in approxi-
431mately 20 % of human BC. Although the established
432HER2-targeted therapies trastuzumab and lapatinib have
433had some success, resistance remains a clinical problem.
434Emerging strategies to circumvent this resistance include
435co-targeting the PI3 K pathway and HER family, pan-HER
436family inhibition, and novel therapies such as T-DM1.
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